We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





FDA Could Issue Emergency Use Authorization for COVID-19 Vaccine Within Weeks After Clinical Trial Data Meet Efficacy Requirements

By HospiMedica International staff writers
Posted on 05 Aug 2020
The US Food and Drug Administration (FDA Silver Spring, MD, USA) could issue an emergency use authorization (EUA) for a COVID-19 vaccine in a “matter of weeks” after clinical trial data meet efficacy requirements, according to a top FDA official.

The EUA would speed up the process of producing the COVID-19 vaccine and making it available for the public. More...
Speaking at a recent online event called the Disease Control and Prevention Summit, Peter Marks, MD, director of the FDA Center for Biologics Evaluation and Research, which approves vaccines, said “We’d like to hope that when (efficacy) happens, it will be a matter of weeks before we could actually potentially have something like an emergency use authorization.” However, on an FDA podcast called FDA Insight, Marks cautioned that such an authorization was still months away. Referring to two vaccine candidates that had entered into advanced clinical trials and were being tested on a large group of people, Marks said that enrolling people in a trial takes time and the vaccine’s effectiveness would be visible only after months, suggesting that a vaccine would become available several months from now.

Instead of the step-by-step process that was usually followed for developing vaccines in order to reduce the risk of financial investment, multiple steps were currently being funded at the same time to move a COVID-19 vaccine quickly, according to Marks, although safety remained the top priority. Calling the leading vaccines that had just entered advanced clinical trials as “trailblazers”, Marks said that they would provide more information for the next vaccine candidates. Given that more than one vaccine was in advanced clinical trials, Marks said that there was a possibility of multiple options becoming available to the people, with one working better in older adults and another causing fewer side effects among certain groups. In that case, Marks suggested that patients should speak with their doctors to choose the best vaccine option.

“Now, how much of it will be deployed and how long that will take I can’t answer today,” said Marks. “But I know there are teams working on that and they’re trying to make that as quick as possible and to make it make as much sense as possible so that the first vaccine that’s ready to go goes out to the people who need it most and that ultimately everyone who wants to get vaccinated can get vaccinated.”

Related Links:
US Food and Drug Administration (FDA)


Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image Credit: Adobe Stock

Emergency Department Campaign Reduces CT Use Without Identified Missed Injuries

Unnecessary head and cervical spine computed tomography (CT) in low-risk trauma patients exposes them to avoidable radiation, prolongs emergency department stays, and increases healthcare costs.... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.